env Gene Products, Human Immunodeficiency Virus
"env Gene Products, Human Immunodeficiency Virus" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteins encoded by the ENV GENE of the HUMAN IMMUNODEFICIENCY VIRUS.
MeSH Number(s)
D12.776.964.775.325.164
D12.776.964.775.562.500
D12.776.964.970.880.325.164
Below are MeSH descriptors whose meaning is more general than "env Gene Products, Human Immunodeficiency Virus".
Below are MeSH descriptors whose meaning is more specific than "env Gene Products, Human Immunodeficiency Virus".
This graph shows the total number of publications written about "env Gene Products, Human Immunodeficiency Virus" by people in Harvard Catalyst Profiles by year, and whether "env Gene Products, Human Immunodeficiency Virus" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 3 | 3 |
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 1 | 2 |
| 2008 | 1 | 6 | 7 |
| 2009 | 5 | 3 | 8 |
| 2010 | 4 | 2 | 6 |
| 2011 | 7 | 4 | 11 |
| 2012 | 5 | 7 | 12 |
| 2013 | 10 | 7 | 17 |
| 2014 | 12 | 8 | 20 |
| 2015 | 8 | 6 | 14 |
| 2016 | 13 | 3 | 16 |
| 2017 | 8 | 12 | 20 |
| 2018 | 12 | 6 | 18 |
| 2019 | 17 | 8 | 25 |
| 2020 | 12 | 5 | 17 |
| 2021 | 9 | 6 | 15 |
| 2022 | 2 | 4 | 6 |
| 2023 | 2 | 6 | 8 |
| 2024 | 1 | 1 | 2 |
Below are the most recent publications written about "env Gene Products, Human Immunodeficiency Virus" by people in Profiles.
-
A VRC13-like bNAb response is associated with complex escape pathways in HIV-1 envelope. J Virol. 2024 Mar 19; 98(3):e0172023.
-
Inhibition of human immunodeficiency virus (HIV-1) infectivity by expression of poorly or broadly neutralizing antibodies against Env in virus-producing cells. J Virol. 2024 Feb 20; 98(2):e0159423.
-
Antibody-directed evolution reveals a mechanism for enhanced neutralization at the HIV-1 fusion peptide site. Nat Commun. 2023 Nov 21; 14(1):7593.
-
Predicted resistance to broadly neutralizing antibodies (bnAbs) and associated HIV-1 envelope characteristics among seroconverting adults in Botswana. Sci Rep. 2023 10 24; 13(1):18134.
-
Relative resistance of patient-derived envelope sequences to SERINC5-mediated restriction of HIV-1 infectivity. J Virol. 2023 10 31; 97(10):e0082323.
-
Alterations in gp120 glycans or the gp41 fusion peptide-proximal region modulate the stability of the human immunodeficiency virus (HIV-1) envelope glycoprotein pretriggered conformation. J Virol. 2023 09 28; 97(9):e0059223.
-
Heavy-chain CDR3-engineered B cells facilitate in vivo evaluation of HIV-1 vaccine candidates. Immunity. 2023 10 10; 56(10):2408-2424.e6.
-
Anti-V1/V3-glycan broadly HIV-1 neutralizing antibodies in a post-treatment controller. Cell Host Microbe. 2023 08 09; 31(8):1275-1287.e8.
-
Conformations of Human Immunodeficiency Virus Envelope Glycoproteins in Detergents and Styrene-Maleic Acid Lipid Particles. J Virol. 2023 06 29; 97(6):e0032723.
-
Characterization of the Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein Conformational States on Infectious Virus Particles. J Virol. 2023 03 30; 97(3):e0185722.